Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted ...
Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.
The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the ...
Based on DESTINY-Breast09 Phase III trial results that showed AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU in combination with pertuzumab reduced the risk of disease progression or death by 44% vs.
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a ...
Based on DESTINY-Breast09 Phase III trial results which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP with a median progression-free survival of ...
A regulatory decision is expected during the first quarter of 2026. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for ...
Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results